• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Nemaura Medical

Nemaura Medical dips on Q1 losses

August 17, 2020 By Sean Whooley

nemaura-medical-logo

Nemaura Medical (NSDQ:NMRD) shares took a slight hit today on first-quarter results that reflected losses of over $1 million. The Loughborough, England-based continuous glucose monitor maker did not report its revenue numbers for the quarter, having posted losses of $1.1 million, or -5¢ per share for the three months ended June 30, 2020, for a 12.1% […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Patient Monitoring, Wall Street Beat Tagged With: Nemaura Medical

Nemaura Medical repurposes its CGM to spot coronavirus fevers

April 1, 2020 By Sean Whooley

nemaura-medical-logo

Nemaura Medical (NSDQ:NMRD) announced today that it is planning to immediately repurpose its SugarBeat continuous glucose monitor (CGM) as a continuous temperature monitor (CTM) to help diagnose fevers in potential cases of COVID-19. The Loughborough, England-based company said in a news release that its inbuilt temperature sensor is capable of continuously tracking body temperature through the […]

Filed Under: Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: coronavirus, COVID-19, Nemaura Medical

Nemaura Medical enters non-binding agreements for its SugarBeat platform

March 10, 2020 By Sean Whooley

Nemaura Medical (NSDQ:NMRD) announced today that it entered into multiple verbal non-binding agreements for its SugarBeat continuous glucose monitor as it seeks to secure regional and global partnerships. The Loughborough, U.K.–based company expects the agreements to lead to discussions over licensing and collaboration, but can’t guarantee that deals will be struck as planned, or at all, […]

Filed Under: Business/Financial News, Diabetes, Featured, Patient Monitoring Tagged With: Nemaura Medical

Nemaura bids for de novo clearance from FDA for SugarBEAT glucose monitor

July 12, 2019 By Danielle Kirsh

nemaura-medical-logo

Nemaura Medical (NSDQ:NMRD) this week said it submitted a De Novo medical device applications to the FDA for its SugarBEAT non-invasive glucose monitor. The Loughborough, England-based company recently successfully completed clinical studies and two summative human factors usability studies needed to support De Novo submission. “We are pleased to have submitted our De Novo 510(k) application […]

Filed Under: Diabetes, Food & Drug Administration (FDA) Tagged With: Nemaura Medical

Nemaura Medical wins CE Mark for SugarBeat CGM

May 30, 2019 By Danielle Kirsh

nemaura-medical-logo

Nemaura Medical (NSDQ:NMRD) said yesterday that it won CE Mark approval for its SugarBEAT continuous glucose monitor. The SugarBEAT CGM is a flexible, disposable patch that’s connected to a rechargeable transmitter and Bluetooth-enabled smartphone app, designed to deliver glucose readings at five-minute intervals throughout the day. The company says the device allows users to spend more […]

Filed Under: Diabetes, Regulatory/Compliance Tagged With: Nemaura Medical

Nemaura prices $2.5m offering to support launch of wearable glucose monitor

December 20, 2018 By Sarah Faulkner

Nemaura logo

Nemaura Medical (NSDQ:NMRD) said this week that it priced a public offering of the company’s common stock and warrants, hoping to reel in $2.5 million in proceeds. The offering is slated to close today. Nemaura plans to use the offering’s proceeds to support the launch of its wearable glucose monitor in Europe, as well as the […]

Filed Under: Diabetes, Featured, Funding Roundup, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Nemaura Medical

Nemaura develops predictive algorithms for continuous glucose monitor

November 9, 2018 By Sarah Faulkner

Nemaura logo

Nemaura Medical (NSDQ:NMRD) said today that it successfully developed predictive algorithms to support alarm functions in its sugarBeat continuous glucose monitoring system. The England-based company touted that its device’s alarm functionality can predict a user’s glucose level five minutes in advance with 98% accuracy, 10 minutes in advance with 95% accuracy and 15 minutes in advance with […]

Filed Under: Diabetes, Featured, mHealth (Mobile Health), Wall Street Beat Tagged With: Nemaura Medical

Nemaura touts data from home-use study of wearable glucose monitor

August 1, 2018 By Sarah Faulkner

Nemaura Medical

Nemaura Medical (NSDQ:NMRD) said today that it launched a study of its wearable glucose monitor in the hopes of winning regulatory approval in the U.S. The England-based company touted positive interim data from the study, focusing on the at-home use of the sugarBeat device. The company’s interim results included findings from 25 patients with either Type […]

Filed Under: Clinical Trials, Diabetes, Featured, Patient Monitoring, Wall Street Beat Tagged With: Nemaura Medical

Nemaura Medical gears up to commercialize glucose monitor

July 17, 2018 By Sarah Faulkner

Nemaura Medical

Nemaura Medical (NSDQ:NMRD) said today that it placed an initial order to its UK-based contract manufacturer for 12,500 rechargeable transmitters, designed as part of the company’s sugarBeat glucose monitoring systems. Nemaura is readying for the commercial launch of its sugarBeat glucose monitor, pending CE Mark approval in the European Union. The device consists of a disposable, […]

Filed Under: Diabetes, Featured, mHealth (Mobile Health), Patient Monitoring, Wall Street Beat Tagged With: Nemaura Medical

Glooko names digital health veteran as CEO | Personnel Moves – April 17, 2018

April 17, 2018 By Sarah Faulkner

Glooko

Glooko named health tech veteran Russ Johannesson as its new chief executive this month, adding that the diabetes data management company’s former CEO, Rick Altinger, is slated to become EVP of corporate development. Johannesson previously served as the chief operating officer of Sharecare, a digital health and wellness platform. Before that he led sales, marketing […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Aerie Pharmaceuticals, depomed, glooko, Glytec, milestonescientific, natera, Nemaura Medical, Orchard Therapeutics, perkinelmer, pneumarespiratory

  • Go to page 1
  • Go to page 2
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS